Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk
To analyze the long-term health outcomes of testicular cancer survivors treated with different chemotherapy regimens, specifically comparing EPx4 and BEPx3.
Key Findings:
Patients treated with EPx4 had 1.55 times the odds of renal impairment compared to BEPx3, and BEPx4 was linked to higher odds of Raynaud phenomenon compared to EPx4.
Interpretation:
Long-term survivors of testicular cancer treated with EPx4 face increased risks of renal, nerve, and hearing complications compared to those treated with BEPx3, highlighting the need for careful long-term health management.
Limitations:
text
Conclusion:
This study highlights the comparable long-term CBM scores between EPx4 and BEPx3, but significant differences in cisplatin-related toxicities, emphasizing the need for careful monitoring of long-term health outcomes, particularly renal and neurological health.
